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Abstract:  
Acetaminophen is among the most commonly used non-opioid analgesics, but significant 
variation exists in its prescribing practices for cirrhosis patients.  Our primary objective was to 
describe the quality of evidence supporting or refuting the use of acetaminophen in patients 
with hepatic dysfunction.  A comprehensive literature review of PubMed, Cochrane Library, 
Web of Science, and International Pharmaceutical Abstracts using the search terms 
“acetaminophen”, “paracetamol”, “chronic liver disease”, “cirrhosis”, and “hepatic disease” for 
studies describing changes in acetaminophen metabolism in patients with hepatic dysfunction 
was conducted. Twelve studies and four abstracts were included. Ten studies and three 
abstracts were pharmacokinetic studies. Two studies and one abstract evaluated the 
association of acetaminophen use and decompensation in the cirrhotic patient.  The level of 
certainty for dosing recommendations obtainable from reviewing the evidence is low due to a 
small number of studies meeting search criteria, small samples sizes, inadequate information 
regarding cirrhosis etiology and compensated versus uncompensated liver disease, and lack of 
information on patient centered health outcomes.  High quality trials are not available to 
support the use of decreased acetaminophen doses in compensated cirrhosis patients.  
Acetaminophen can be a safe analgesic in patients with compensated hepatic dysfunction after 
careful analysis of patient specific factors.    
 
Keywords:  acetaminophen, paracetamol, cirrhosis, chronic liver disease, dose 
Introduction:  
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The United States opioid epidemic is a public health crisis that accounted for 42,249 deaths in 
2016 and a five-fold increase in opioid overdoses since 1999 (1).  The European Association for 
the Study of the Liver recommend against using NSAIDs (non-steroidal anti-inflammatory drug) 
in patients with cirrhosis and ascites due to concerns for increased rates of hepatorenal 
syndrome (2).  This has prompted renewed interest in non-opioid analgesics such as 
acetaminophen for the treatment of acute and chronic pain. An estimated 50 million Americans 
use acetaminophen weekly and it is contained in more than 600 over-the-counter (OTC) and 
prescription products (3, 4).   
Acetaminophen is well absorbed orally and therapeutic doses are biotransformed primarily in 
the liver (5).  Two saturable pathways exist that produce non-toxic metabolites, the sulfation 
and glucuronidation pathways (5, 6).  Under normal circumstances, 70-90% of acetaminophen 
is metabolized through these pathways, with a small portion excreted unchanged in the urine. 
The remainder is transformed to a highly reactive metabolite primarily via the cytochrome P450 
(CYP) 2E1 enzyme system to a hepatotoxic moiety, N-acetyl-p-benzoquinoneimine (NAPQI), 
which is further metabolized to inactive and non-toxic cysteine and mercapturic acid 
conjugates. The glucuronidation pathway is not fully developed at birth, but increases with age 
until it reaches adult values at approximately age 10 (7).  The rate of sulfation is unchanged 
with age and compensates for decreased glucuronidation capacity when metabolizing 
acetaminophen in children less than 10 years (8).   CYP2E1 enzyme activity increases at birth 
and approaches adult levels by 1-2 years of age (9).   
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Acetaminophen is the leading cause of acute liver failure (ALF) in the United States, accounting 
for approximately 50% of cases (10).  Variability in acetaminophen prescribing practices exists 
in all patient populations, but is of greater significance in hepatically impaired patients who 
may be less likely to recover from drug induced liver injury (DILI) than healthy individuals (11).   
It was observed among ALF study group institutions that 48% of acetaminophen overdoses 
were unintentional (12).  These statistics draw attention to the potential for harm among 
acetaminophen users.  
  Several studies have drawn attention to the lack of understanding among patients about safe 
acetaminophen use in chronic liver disease (CLD) and physicians’ disparate practices for 
maximum daily doses of acetaminophen.  A recent study by Saab et al noted a significant 
knowledge deficit in liver disease patients about appropriate acetaminophen use (13).  The 
investigators surveyed 401 outpatients regarding their understanding of acetaminophen 
dosing.  A recommended maximum daily acetaminophen dose of < 3 g/day was identified by 
7.5% of patients. Approximately 20% of surveyed patients believed that acetaminophen should 
be completely avoided in liver disease. Physician evaluation of potential harms caused by 
acetaminophen varies by specialty and experience. Rossi et al surveyed Philadelphia area 
physicians regarding their recommendations for acetaminophen use in cirrhosis and chronic 
hepatitis patients (14).   Survey respondents were more likely to advise their patients to avoid 
acetaminophen than a NSAID.  Gastroenterologists were less likely than family medicine or 
internal medicine physicians to recommend avoiding acetaminophen use in compensated 
cirrhosis (OR: 0.09; 95% CI: 0.01-0.60), decompensated cirrhosis (OR: 0.05; 95% CI: 0.01-0.21), 
and chronic hepatitis (OR: 0.19; 95% CI: 0.01-1.07).  Banerjee et al. reported similar survey 
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findings among gastroenterology fellows, internal medicine residents, and fourth year medical 
students in the Greater Washington D.C. area (15).  Internal medicine and medical students 
noted their primary reason for using NSAIDs over acetaminophen was concern about worsening 
patients’ CLD (16).  When survey respondents did use acetaminophen in CLD patients they were 
more likely to prescribe <  2 g/day than 4 g/day regardless of liver disease severity (17).  These 
studies highlight the inconsistent understanding of appropriate OTC analgesic use in CLD 
patients and the diverse prescribing practices among healthcare practitioners.  
The FDA released a statement in 2003 regarding medication dosing and labeling 
recommendations in patients with impaired hepatic function (18).  While acetaminophen’s use 
in the United States predates this document by many years, this statement represents current 
best practices.   Key aspects of these non-binding recommendations include use of the Child-
Pugh classification for categorization of the severity of hepatic dysfunction and development of 
dose adjustments for medications if the pharmacokinetics (PK) are substantially altered by 
hepatic dysfunction. The FDA uses the example of a two-fold or greater increase in the area 
under the curve. This document does not provide further guidance for dosing in hepatic 
impairment and does not make specific recommendations for when dose adjustments should 
be made in pediatric patients. 
Recommendations for appropriate acetaminophen use in chronic liver disease patients are 
further complicated by a lack of consensus from professional organizations.   The American 
Liver Foundation issued a 2006 press release advising CLD patients to consult with their 
physician before taking acetaminophen, but did not offer guidance to prescribers on 
recommended regimens (19).  Similarly, oral acetaminophen product labeling warns patients 
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with liver disease to seek physician guidance prior to starting acetaminophen, but does not 
provide specific dose recommendations (20).  The American Geriatrics Society’s (AGS) 2009 
guideline on Pharmacological Management of Persistent Pain in Older Adults empirically 
suggests to decrease the maximum daily acetaminophen dose by 50-75% in patients with 
hepatic disease or a history of alcohol abuse (21).  The guideline authors did not elaborate on 
this recommendation or reference supporting literature.  The American Gastroenterological 
Association (AGA) and American Association for the Study of Liver Disease (AASLD) do not 
address acetaminophen dosing recommendations for CLD patients.  Four review articles 
provide recommendations for acetaminophen use in cirrhosis patients.  Chandok and Watt 
advised providers’ treating patients with cirrhosis that acetaminophen use for greater than 14 
days should not exceed 2-3 g/day, but 4g/day may be appropriate if use for less than 2 weeks is 
anticipated (22).  Imani et al advocated for the same dosing in a 2014 review (23).  Lewis 
endorsed use of the lowest effective acetaminophen dose in liver disease patients due to its 
narrow therapeutic index with a maximum daily dose (MDD) of 2-3g/day (11).  Hayward et al 
published a comprehensive review of acetaminophen metabolism in patients with varying 
degrees and etiologies of liver disease (24).  Their conclusions were that acetaminophen is a 
safe analgesic in all populations but made nonspecific recommendations for cautious 
prescribing based on individual patient characteristics.  In light of these conflicting 
recommendations, our goal was to critically evaluate the quality of evidence used to formulate 
the acetaminophen dose recommendations for chronic liver disease patients.   
Methods: 
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Relevant human studies published or in press before April 2018 were identified in PubMed, 
Cochrane Library, Web of Science Core Collection, and International Pharmaceutical 
Abstracts/EBSCOhost using the search terms “acetaminophen”, “paracetamol”, “chronic liver 
disease”, “cirrhosis”, and “hepatic disease”.  Additionally, we cross-referenced recent review 
articles to ensure we independently identified pertinent literature.  The manufacturers of 
intravenous and branded acetaminophen were contacted for unpublished trials. We reviewed 
the U.S. National Library of Medicine ClinicalTrials.gov and the World Health Organization 
International Clinical Trials Registry Platform for ongoing, unpublished, or previously 
overlooked trials. We reviewed ProQuest Dissertations & Theses Global, OpenSIGLE, OAIster, 
and the New York Academy of Medicine Grey Literature report that contains grey literature 
from 1999 to 2016.  This search strategy was developed in conjunction with a research 
librarian.  
Our literature review was narrowed to include adult and pediatric patients with diagnosed 
chronic liver disease.  We excluded studies of patients with active alcohol use but without 
documented liver disease. Studies that were not published in English were also omitted.  The 
authors met to review their findings and discussed their rating rationale until consensus was 
reached.  Each author independently assessed the studies that met the inclusion criteria using a 
validated checklist to evaluate their quality.  However, studies that were only published in 
abstract form were not analyzed with a validated checklist.   
Multiple checklists exist to assess the quality of evidence of randomized, placebo controlled 
trials, but there are limited options for assessing the validity of pharmacokinetic studies. In 
2015 a group of stakeholders released a checklist delineating optimal practices in reporting 
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pharmacokinetic studies (25).  The ClinPK checklist (Table 1) was released in an effort to ensure 
adequate information is described to draw unbiased conclusions from reported studies.  The 
checklist includes domains evaluating known pharmacokinetic data, study methodology, 
presentation of results, limitations, and funding. While no standard cutoffs are defined to 
demarcate high, intermediate, or low quality studies, the authors determined that it was 
important to quantify the quality of information presented in the studies used to make dosing 
recommendations in patients with CLD. Each study was evaluated to determine the number of 
24 checklist items that were reported.  
The assessment tool developed by Downs and Black is validated in both randomized and 
nonrandomized trials to quantify study quality (26). We utilized it to analyze case control 
studies that met our inclusion criteria.  Clarity of reporting, internal validity, external validity, 
and power are all assessed. Previous reviews utilizing this have suggested studies scoring from 
26-28 are excellent, 20-25 are good, 15-19 are fair, and <14 are poor quality (27). 
Results: 
Twelve studies and four abstracts were identified as outlined in Figure 1. The population, 
design, intervention, outcomes, and evaluation of the studies and abstracts that met our 
criteria are described in Table 2 (6, 28-42).  Ten studies were evaluated with the ClinPK checklist 
(6, 28-32, 34, 36, 37, 42). Their scores ranged from 6 to 16 with a median score of 10.5.  All the 
studies met the ClinPK checklist criteria for study title, rationale, specific objectives, drug 
preparation and administration characteristics, and results reporting (25).  Per the ClinPK 
checklist criteria eight of ten studies had an appropriate abstract, description of the 
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bioanalytical methods, commented on subjects lost to follow-up, and quantification of missing 
or excluded data.  None of the studies satisfactorily reported concomitant medications, drug 
bioavailability, extracorporeal drug removal, covariates used in population pharmacokinetic 
models, and potential conflicts of interest as defined by the ClinPK checklist.  Limited 
information describing relevant variables that would explain inter-patient pharmacokinetic 
differences was the most clinically significant ClinPK checklist omission for the purposes of our 
review.  The study by Zapater et al. was the only study to describe its limitations, factors 
influencing PK variability, the formulas for calculated variables, and participant eligibility criteria 
according to the ClinPK checklist (42).   Only one study described pharmacokinetic modeling 
methods/software (31).   Two studies included the statistical modeling methods/software (31, 
42) and funding sources (36, 42).  Many of the omissions in the ClinPK checklist criteria reflect 
the changing standards for pharmacokinetic studies (25).      
As a whole, the studies reported inconsistent endpoints most of which lack clinical significance. 
All studies used individual protocols regarding the number and timing of samples drawn. The 
majority of studies report urinary metabolites, acetaminophen concentrations, or changes in 
liver enzymes.  Only the Arnman et al., El-Azab et al., and Zapater et al. studies report AUC in 
the placebo and intervention groups (29, 32, 42).  None of the three studies meet the FDA AUC 
criteria for dose adjustment.  All studies reporting AUC are single dose studies which prevents 
meaningful conclusions from being drawn from this data and do not contribute to determining 
if multiple dose regimens are appropriate in patients’ with cirrhosis.  
Current standards for staging liver disease severity and dosing medication advise use of the 
Child-Pugh score. The studies by Gelotte et al., Gunawan and Carey, and Zapater et al. 
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calculated the Child-Pugh score for participants, leaving questions about disease severity in the 
remaining studies (38, 39, 42).  Few studies defined concurrent disease states, concomitantly 
administered medications, or confirmed cirrhosis diagnosis and severity.  
Cormack et al., Fevery and de Groote, Gelotte et al., Leung et al. 1990, and Leung and Critchley 
1991 do not report t1/2 of acetaminophen, but the remaining pharmacokinetic studies do (6, 
31, 34, 38, 41). Unfortunately, there are no codified recommendations for dose adjustments 
based on this data.  The Benson study and the abstract by Gunawan and Carey report changes 
to liver enzymes (30, 39).  The studies by Forrest et al. 1979, Leung et al. 1990, and Leung and 
Critchley 1991 and the abstract by Gelotte et al. report urinary metabolite excretion (6, 37, 38, 
41).  While the studies that do not report AUC or t1/2 add to our body of knowledge, the other 
endpoints obtained can be difficult to use in routine clinical practice. The above limitations are 
compounded by the study investigators lack of elaboration on the clinical applicability of their 
findings. 
The two retrospective case control studies by Khalid et al. and Fenkel et al. were assessed using 
the Downs and Black checklist and were determined to be fair quality (Table 1) (26, 33, 40). 
Both studies assessed the risk of decompensation in patients with cirrhosis who were taking 
over the counter analgesics. These studies relied on questionnaires to evaluate frequency, type, 
and dose of over the counter analgesics. The dependence on recall could introduce bias. The 
study by Fenkel et al. was the most comprehensive in delineating type of liver disease but did 
not calculate a Child-Pugh score for enrolled patients (33).  The Khalid study was more 
comprehensive in that patients with decompensated cirrhosis, non-decompensated cirrhosis, 
and patients without cirrhosis were compared, which may eliminate some bias (40). There was 
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a much lower rate of concurrent alcohol use in the Fenkel study as compared to the Khalid 
study (33, 40).  
Discussion: 
A primary limitation to applying the results of pharmacokinetic studies to acetaminophen 
dosing recommendations lies with inherent interpatient variability within patients’ in the same 
Child-Pugh class and poor differentiation of cirrhosis etiology  Current drug dosing 
recommendations depend on the Child-Pugh score as a marker of the liver’s capacity of the 
liver to metabolize medications. This score is a combined subjective and objective assessment 
of cirrhosis severity and likelihood of mortality (43). It assesses total bilirubin, albumin, PT/INR, 
ascites, and encephalopathy and segregates patients into three classes: A, B, and C. Class A 
patients have the lowest mortality, class C patients the highest.  There is significant 
heterogeneity among patients with the same Child-Pugh class. Drug metabolism in cirrhosis is 
acknowledged to be impaired, but controversy exists in the significance and clinical utility of 
using predictive scores such as Child-Pugh to assess severity of metabolic changes. Kovarik et al. 
studied the pharmacokinetic changes of everolimus in patients with moderate hepatic 
dysfunction (defined as Child-Pugh scores 7-9) (44).  The area under the curve (AUC) of 
everolimus ranged from 69-103 ng x h/ml in healthy patients to 146-328 ng x h/ml in a small 
number of patients with a Child-Pugh score of 7. Similar changes were seen in prolongation of 
half-life (t1/2) between the groups.  The variability of these measures is notably greater in 
patients with hepatic impairment as compared to healthy patients.  This variability in AUC is 
greater when patients with Child-Pugh scores of 8 or 9 are considered in the analysis. In 
contrast, Albarmawi et al. used Child-Pugh scores in patients with and without hepatic 
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dysfunction to evaluate pharmacokinetic variability of midazolam (43).  These authors 
determined that the Child-Pugh score was an acceptable predictor of the CYP3A subfamily 
activity despite variation in midazolam t1/2 within the same Child-Pugh class.   
In addition to variability within patients with the same Child-Pugh class, the etiology of liver 
disease may have an effect on the activity of enzymes involved in acetaminophen metabolism 
(45).  Patients’ with non-alcoholic steatohepatitis have demonstrated higher expression of 
CYP2E1, which may lead to increased risk of hepatotoxicity with acetaminophen exposure.  This 
variability has been further documented by George et al. (46).  In their study of expression of 
the CYP enzymes, they determined that patients with hepatocellular disease had preserved 
levels of CYP2E1 while those patients with cholestatic dysfunction had reduced expression of 
the same enzyme. The authors further determined that the variability in this enzyme was 11-
fold in healthy patients versus 44-fold in patients with advanced hepatic disease.  The increased 
interpatient variation in enzymatic activity in patients with hepatic disease adds to the 
challenges of providing an optimized yet safe dose.  
Multiple other factors limit the ability to draw robust conclusions regarding appropriate dosing 
from the evaluated studies. Factors affecting internal validity include short study duration, 
recruitment of small study populations, lack of subject randomization and poorly defined 
timeframes for subject enrollment. Patients received multiple doses of acetaminophen in the 
studies by Andreasen and Hutters, Benson, and the abstract by Gelotte et al. (28, 30, 38).  We 
have observed in our clinical practice that many providers are willing to administer single doses 
of acetaminophen to compensated cirrhotic patients, the more valid clinical question relates to 
multiple dose regimens. Having only three studies addressing longer term use of 
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acetaminophen prevents strong conclusions from being drawn. External validity is limited by a 
heterogeneous and poorly defined population which is amplified by dated studies and changing 
standards for diagnosis and categorization of liver disease. Study population heterogeneity is 
often perceived as strengthening the external validity of data, but with small study populations, 
poorly defined etiology and severity of hepatic dysfunction, and inconsistent endpoints it is 
difficult to apply this data to specific patients. 
Applying the ClinPK checklist to studies published well before the development of this quality 
measure highlights the changing standards for conducting pharmacokinetic research and 
reporting (25).  We acknowledge applying current standards to older studies will lead to 
apparent lower scores. Many items on the list do not apply to the studies we identified 
(extracorporeal drug removal, bioavailability), but we chose to comprehensively assess all 
studies. 
Other authors have suggested the absence of solid evidence can be reconciled with clinical 
practice by evaluation of risk factors.   A review article by Lewis in 2002 provided suggestions 
for safe use of potentially hepatotoxic medications in CLD patients which included an 
evaluation of concomitant alcohol use, metabolic pathway inducers, and medications that 
decrease glutathione stores (11).  Data on substances that reduce glutathione stores are 
limited, the Natural Medicines Comprehensive Database only identifies acetaminophen and 
alcohol consumption (47).  The impact of glutathione levels in patients with cirrhosis is under 
debate.  Two small studies have demonstrated conflicting results (48, 49).  One study of 14 
patients with cirrhosis reflects glutathione stores comparable to patients without hepatic 
impairment, while a study with 3 patients with cirrhosis had higher levels of glutathione than 
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placebo controls. If these study findings are valid, glutathione depletion may not be a risk factor 
for further hepatic damage in non-alcoholic patients with cirrhosis taking acetaminophen. Lewis 
recommended liver disease patients undergo more frequent liver function tests (LFTs) and 
clinical monitoring than healthy patients to detect trends indicating worsening liver function 
(11).  The author did not specify a recommended frequency for LFT, clinical monitoring, or 
guidance on when to stop acetaminophen. Two studies of chronic acetaminophen use in OA 
and asthma patients without CLD suggest obtaining INR, albumin, and bilirubin labs if ALT and 
AST exceeds three times the upper limit of normal (ULN) (50, 51).  These studies routinely 
monitored patients’ ALT and AST as part of the study protocol, but no patients developed liver 
enzymes three times the ULN to provide clinical context on when to stop acetaminophen.  Since 
the studies excluded CLD patients, the investigators’ practice of monitoring ALT/AST does not 
have external validity for cirrhosis patients because they may not adequate viable hepatocytes 
to express liver enzymes with advanced disease (52).  Further, routine practice does not dictate 
regular aminotransferase monitoring.   The cases in supplement 1 provide two scenarios to 
consider the appropriateness of acetaminophen use in patients with chronic liver disease 
through application of the patient specific factors discussed above (2, 45, 53).   
This risk benefit analysis should include consideration of the paucity of evidence suggesting that 
chronic scheduled use of the maximum recommended doses of acetaminophen provide better 
pain relief than lower doses.   At the time of this writing there is no available literature 
evaluating improved analgesia with acetaminophen 4 g/day compared to < 3 g/day.  In a 2006 
systematic review McQuay and Moore reported a number needed to treat (NNT) of 9 (95% CI:  
6-20) to achieve at least 50% maximum total pain relief for a single dose of acetaminophen 
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1000mg compared to a 500-650mg dose (54).  This finding is similar to the results of a 2008 
Cochrane Database Systematic Review which noted a NNT of 3.5 (95% CI: 2.7-4.8) for a single 
acetaminophen 500mg dose, NNT of 4.6 (95% CI: 3.9-5.5) for acetaminophen 600-650mg, and 
NNT of 3.6 (95% CI:  3.4-4) for acetaminophen 1000mg to achieve at least 50% pain relief in 
post-operative patients (55). These dose response results suggest that empiric acetaminophen 
dose reductions may not result in a clinically significant decrease in pain control regardless if a 
patient has CLD or normal hepatic function.  Therefore CLD patients may not have 
compromised analgesia when adhering to an expert opinion maximum daily acetaminophen 
dose of 2-3 g/day.  Documented increases in t1/2 and AUC, potential equianalgesic effects of 
reduced doses, and an emphasis on patient safety coupled with clinical judgement make 
reductions in the maximum daily dose reasonable.   
Conclusion: 
As clinicians, we are seeking robust data to draw from in making evidence-based 
recommendations for patient care. The limited side effect profile at therapeutic doses and low 
cost make acetaminophen an attractive non-opioid analgesic option for pain management in 
many patients. While the studies have significant limitations, the body of evidence suggests 
that acetaminophen is an acceptable option in a compensated cirrhotic patient, particularly 
when incorporating the expert opinion dosing and monitoring recommendations advocated 
above. The specific recommendation of limiting acetaminophen doses to less than 2-3 grams 
per day is not supported by high quality trials, particularly when acetaminophen is used 
chronically. There is insufficient evidence to arbitrarily reduce doses or avoid the use of 
acetaminophen in cirrhosis patients.  
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Figure 1: PRISMA flow diagram of studies identified, excluded, and included in 
systematic review. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Reasons that studies were excluded:  wrong comparator group (n=2), wrong patient 
population (active alcohol use) (n=11), wrong study design (n=11), wrong outcomes 
(n=8), background information (n=16), non-English studies (n=4) 
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Table 1:  ClinPK Checklist 
  Checklist Item   
 Title/Abstract Reported on 
Page Number 
1 The title identifies the drug(s) and patient population(s) studied.  
2 The abstract minimally includes the name of the drug(s) studied, the 
route of administration, the population in whom it was studied, and the 
results of the primary objective and major clinical pharmacokinetic 
findings. 
 
 Background  
3 Pharmacokinetic data (i.e., absorption, distribution, metabolism, 
excretion) that is known and relevant to the drugs being studied is 
described.   
 
4 An explanation of the study rationale is provided  
5 Specific objectives or hypotheses is provided  
 Methods  
6 Eligibility criteria of study participants are described  
7 Co-administration (or lack thereof) of study drug(s) with other 
potentially interacting drugs or food within this study is described 
 
8 Drug preparation and administration characteristics including dose, 
route, formulation, infusion duration (if applicable) and frequency are 
described. 
 
9 Body fluid or tissue sampling (timing, frequency and storage) for 
quantitative drug measurement is described. 
 
10 Validation of quantitative bioanalytical methods used in the study are 
referenced or described if applicable. 
 
11 Pharmacokinetic modeling methods and software used are described, 
including assumptions made regarding the number of compartments and 
order of kinetics (zero, first or mixed order). 
 
12 For population pharmacokinetic studies, covariates incorporated into 
pharmacokinetic models are identified and described. 
 
13 Formulas for calculated variables (such as creatinine clearance, body 
surface area, AUC, and adjusted body weight) are provided or 
referenced. 
 
14 The specific body weight used in drug dosing and pharmacokinetic 
calculations are reported (i.e., ideal body weight vs. actual body weight 
vs. adjusted body weight) 
 
15 Statistical methods including software used are described  
 Results  
16 Study withdrawals or subjects lost to follow- up (or lack thereof) are 
reported. 
 
17 Quantification of missing or excluded data is provided if applicable.  
18 All relevant variables that may explain inter- and intra-patient 
pharmacokinetic variability (including: age, sex, end-organ function, 
ethnicity, weight or BMI, health status or severity of illness, and 
 
pertinent co-morbidities) are provided with appropriate measures of 
variance. 
19 Results of pharmacokinetic analyses are reported with appropriate 
measures of precision (such as range or 95% confidence intervals) 
 
20 Studies in patients receiving extracorporeal drug removal (i.e., dialysis) 
should report the mode of drug removal, type of filters used, duration of 
therapy and relevant flow rates. 
 
21 In studies of drug bioavailability comparing two formulations of the 
same drug, F (bioavailability), AUC, Cmax (maximal concentration) and 
Tmax (time to maximal concentration) should be reported. 
 
 Discussion/Conclusion  
22 Study limitations describing potential sources of bias and imprecision 
where relevant should be described 
 
23 The relevance of study findings (applicability, external validity) is 
described 
 
 Other Information  
24 Funding sources and conflicts of interest for the authors are disclosed.  
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Table 2:  Study Characteristics and Outcomes 
Reference 
(Author/year) 
Study population Study design Intervention Outcome(s) (p-value/CI) Checklist 
score  
Andreasen and 
Hutters (1979) 
[30] 
Pilot phase:  
Cirrhosis (n=11); 
controls (n=12) 
 
 
PK study 
 
Paracetamol 1000 mg 
PO x 1 dose  
 
t1/2 (hr):  
 cirrhotics: 3.7+0.8  
 controls: 2.1+0.6 
(p<0.01) 
 
ClinPK 10 
Follow-up: 
Cirrhosis (n=4); 
controls (n=9) 
PK study Paracetamol 1000 mg 
PO  
TID x 5 days 
Plasma acetaminophen 
concentration before second 
daily dose (mcg/ml): 
 cirrhotics 9.2  
 controls: 3.2 (p<0.01) 
 
t1/2: values not reported (p = 
ns)  
Arnman and 
Olsson (1978) 
[31] 
Cirrhosis (n=21); 
secondary liver cancer 
(n=4); controls (n=15) 
 
PK study Paracetamol 15 mg/kg 
PO x 1 dose 
t1/2 (hr):  
 controls: 2.9+1.5 
 cirrhotics 4.75 + 2.4 
 liver cancer: 4.7+1.6 
p<0.01 for controls vs 
cirrhotics 
 
AUC (6 hour):  
 controls: 2.8 + 0.9 mcg 
x min/ml 
 cirrhotics: 4.2 + 1.1 
mcg x min/ml  
p<0.001 for controls vs 
cirrhotics 
ClinPK 12 
Benson (1983) 
[32] 
Pilot phase: 
Cirrhosis (n=6) 
 
 
PK study 
 
Acetaminophen 1000 
mg PO four times 
daily  X 5 days 
Mean acetaminophen t1/2 (hr): 
3.42 +2.5 
 
 
ClinPK 11 
Follow-up:  
Stable, chronic liver 
disease (n = 20) 
Prospective, 
double-blind 
placebo 
controlled 
crossover PK 
study 
1000 mg PO four 
times daily  X 13 days 
SGOT (units) (AST):  
 baseline: 42.5 (SD 
26.3)  
 acetaminophen period: 
39.5 (SD 23.1) 
 placebo period: 55.0 
(SD 71.6) 
 
SGPT (units) (ALT):  
 baseline: 58.6 (SD 
55.7)  
 acetaminophen period 
53.3 (SD 48.8) 
 placebo period 77.3 
(SD 126.2)  
 
Reported as no difference 
Cormack et al. 
(2006) [33] 
Patients age 3-15 with 
CLD (n=16)  
PK study Acetaminophen 40 
mg/kg PR X 1 dose 
(rounded to 
combinations using 60, 
125, 240, or 500 mg. 
Doses >1000 mg were 
given).  
Mean acetaminophen Cmax: 
11.4 mg/L 
ClinPK 15 
El-Azab et al. 
(1996) [34] 
Young healthy controls 
(n=4), 
PK study Acetaminophen 1000 
mg PO X 1 dose  
Mean acetaminophen plasma 
t1/2 (hr):  
ClinPK 10 
elderly healthy controls 
(n=4), 
young CLD (n=4), 
elderly CLD (n=4) 
 
 young healthy controls 
= 2.4 + 0.3 
 young CLD = 4.1 + 
0.1 (p < 0.05) 
 elderly healthy 
controls = 2.8 + 0.2 
 elderly CLD = 4.2 + 
0.2 (p < 0.05) 
 
AUC (0-∞)(mcg•min/mL):  
 young healthy controls 
= 3.55 + 0.12 
 young CLD: 4.60 + 
0.29; (p < 0.05) 
 elderly healthy 
controls = 2.46 + 0.15 
 elderly CLD: 3.47 + 
0.14; (p < 0.05) 
 
Fenkel et al. 
(2010) [35] 
Cirrhotic cases 
admitted to hospital 
with liver associated 
events (n=90) 
Controls: outpatients 
with a diagnosis of 
cirrhosis without a 
hospitalization for 3 
months (n=126) 
Case control Recall of 
acetaminophen, 
ibuprofen, naproxen, 
aspirin, and alcohol 
use in last 30 days 
Rate of acetaminophen use 
prior to hospitalization: 
 cirrhotic cases: 34% 
 controls: 26% (p=NS) 
 
APAP use in last 30 days not 
associated with hospitalization 
(OR: 0.59, 95% CI: 0.25-1.24, 
p=0.161) 
 
Downs and 
Black 15 
Fevery and de 
Groote (1969) 
[36] 
Controls (n=8) 
Hepatitis (n=12) 
Cirrhosis (n=14) 
PK study N.A.P.A 10 mg/kg Serum levels unconjugated 
N.A.P.A. at 3 hrs (mcg/ml): 
 Controls: 1.29 + 0.78 
 Hepatitis: 1.92 + 1.01 
 Cirrhosis: 2.80* + 1.25 
Serum levels unconjugated 
N.A.P.A. at 6 hrs mcg/ml): 
 Controls: 0.76 + 0.5 
 Hepatitis: 1.22 + 1.01 
 Cirrhosis: 2.36* + 1.36  
p  < 0.01 for cirrhosis 
compared to controls 
ClinPK 6 
Forrest et al. 
(1975) [37] 
CLD patients who 
received 
acetaminophen (n=14) 
PK study Paracetamol 1500mg 
PO X 1 dose 
10/14 CLD patients who 
received acetaminophen had a 
prolonged t1/2 (hr) 
 mean CLD t1/2 (hr): 
3.15 (Range: 1.5-7) 
Unable to 
evaluate, 
published 
in abstract 
form only 
Forrest et al. 
(1977) [38] 
CLD (n=23) PK study Paracetamol 1500 mg 
PO X 1 dose 
 
Mean paracetamol plasma t1/2 
(hr):  
 CLD = 2.9 +  0.3 
 healthy controls* = 2.0 
+  0.4 
ClinPK 9 
Forrest et al. 
(1979) [39]  
Severe CLD (n=7), 
mild CLD (n=8), and 
healthy controls (n=8) 
 
PK study  Paracetamol 1500 mg 
PO X 1 dose 
 
Mean paracetamol plasma t1/2 
(hr):  
 healthy controls = 2.43 
+  0.19 
 mild CLD = 2.16 + 
0.54 
 severe CLD = 4.25 + 
1.15 (p < 0.001) 
ClinPK 12 
 
Mean urine cysteine conjugate 
(% of dose):   
 healthy controls = 3.8 
+ 0.1 
 mild CLD = 4.4 + 0.6 
 severe CLD: 4.2 + 0.9  
 
Mean urine mercapturate 
conjugate (% of dose): 
 healthy controls = 4.8 
+ 0.2 
 mild CLD = 4.3 + 0.7 
 severe CLD: 4.2 + 0.6  
Reported as no difference for 
cysteine or mercapturate 
conjugates. 
Gelotte et al. 
(2007) [40] 
Hepatocelluar cirrhosis 
secondary to hepatitis 
C and/or alcohol abuse 
with Child-Pugh: 7-9 
(n=12); healthy 
matched controls 
(n=13) 
PK study Acetaminophen 
1000mg PO four times 
daily X 4 days 
Increased total acetaminophen 
clearance from first to final 
doses  
 hepatic impaired 
(p=0.037) 
 matched controls 
(p<0.001) 
 
Fractional amount of 
glucuronide excreted 
 hepatic impaired: 
40.2+13.3% to 
52.1+16.4% (p<0.001) 
Unable to 
evaluate, 
published 
in abstract 
form only 
 matched controls: 
49.0+7.4% to 
60.8+11.1% (p=0.008) 
 
Gunawan and 
Carey (2002) 
[41] 
Patients in hepatology 
and liver transplant 
clinics (n=217 total; n 
= 174 used 
acetaminophen; n = 43 
no acetaminophen use 
Survey Survey regarding 
acetaminophen use in 
last 4 days; advice 
received about 
acetaminophen use, 
change in severity of 
cirrhotic 
complications,  
Medical records: 
LFTs, CLD etiology, 
presence of cirrhosis or 
severe fibrosis, Child-
Pugh Score 
 96 patients had 
cirrhosis or severe 
hepatic fibrosis 
 55% of patients told to 
avoid acetaminophen 
by a provider 
 29% of patients told to 
avoid acetaminophen 
from a non-medical 
source 
 No increases in LFTs 
or cirrhosis 
complications in 
patients using 
acetaminophen 4g/day 
versus those who did 
not use acetaminophen 
 Child-Pugh score was 
not higher in cirrhosis 
or severe hepatic 
fibrosis patients who 
used acetaminophen 
versus those who did 
not use acetaminophen 
 
Unable to 
evaluate, 
published 
in abstract 
form only 
Khalid et al. 
(2009) [42] 
Hospitalized cirrhotic 
cases (n=91), non-
hospitalized cirrhotic 
controls (n=153), non-
cirrhotic hospitalized 
controls (n=89) 
Retrospective 
case-control 
study 
Recall of OTC 
medication use over 
previous 30 days 
Rate of acetaminophen use:  
 cirrhotic cases: 19% 
 non-hospitalized 
cirrhotic controls: 25% 
 non-cirrhotic controls: 
42% (p = 0.001 for all 
comparisons) 
Downs and 
Black 19 
Leung et al. 
(1990) [43] 
Cirrhosis secondary to 
hepatitis B (n=29); 
cirrhosis secondary to 
chronic alcohol 
consumption (n=13), 
untreated 
hepatocellular 
carcinoma (n=8) 
PK study Paracetamol tablets 1.5 
g PO x 1 dose 
Urine cysteine conjugate (%): 
 cirrhosis secondary to 
HBV: 5+2 
 cirrhosis secondary to 
EtOH: 4+2 
 HCC:11+3  
 
Urine mercapturic acid 
conjugates (%): 
 cirrhosis secondary to 
HBV: 4+1 
 cirrhosis secondary to 
EtOH: 4+2 
 HCC: 9+3  
(p < 0.05 for HCC compared 
to patients without 
malignancy) 
Unable to 
evaluate, 
published 
in abstract 
form only 
Leung and 
Critchley 
(1991) [6] 
Cirrhosis secondary to 
CHBV (n=39); HCC 
(n=19);  healthy 
controls (n=26) 
PK study Paracetamol 1500 mg 
PO x 1 dose 
Urine cysteine conjugate (%):  
 controls: 4+1 
 CHBV: 5+2 
 HCC:12+3  
(p < 0.0001 for HCC 
compared to CHBV or 
controls) 
ClinPK 10 
 
Urine mercapturic acid 
conjugates (%): 
 controls: 3+1 
 CHBV: 5+2 
 HCC: 10+3  
(p < 0.0001 for HCC 
compared to CHBV or 
controls) 
Zapater et al. 
(2004) [44] 
CLD (n=14), 
healthy controls (n=7) 
PK study Acetaminophen 1000 
mg PO X 1 dose  
Mean acetaminophen plasma 
t1/2 (hr): 
 healthy controls = 2.0 
+  0.4 
 all CLD = 3.8 + 1.1; (p 
= 0.01) 
 mild-moderate CLD = 
3.7 + 1.3 
 severe CLD = 4.0 + 
0.6 
 
AUC (0-6h)(mg•h/L):  
 healthy controls = 38.8 
+ 4.3 
 all CLD: 67.4 + 22.4; 
(p < 0.05) 
 mild to moderate CLD 
= 64.6 + 25.0 
 severe CLD: 72.0 + 
18.5 
ClinPK 16 
Legend: 
CHBV = chronic hepatitis B virus infection 
CLD = chronic liver disease 
EtOH = alcohol 
HCC = hepatocellular carcinoma 
N.A.P.A. = N-acetyl-p-aminophenol (acetaminophen) 
OTC = over the counter 
PK = pharmacokinetic  
PO = by mouth 
PR = per rectum 
APAP = acetaminophen or paracetamol 
SUL = sulfates 
GUL = glucuronides  
SGOT = serum glutamic oxaloacetic transaminase 
SGTP = serum glutamic pyruvic transaminase 
ALT = alanine aminotransferase 
AST =aspartate amino transferase 
*= healthy controls from previous studies    
 
Supplement 1: 
Case 1: 
 A 66 year-old female patient with a past medical history significant for nonalcoholic fatty liver 
disease, cirrhosis (Child-Pugh class B),  hypertension, stage 3 chronic kidney disease, and 
osteoporosis  presents to her primary care physician with worsening bilateral knee pain.  The 
patient reports that her knee pain is impairing her ability to comfortably ambulate.  She self treats 
her knee pain with as needed OTC naproxen approximately three times a week.  The patient has 
not been hospitalized in over a year.  She does not drink alcohol.  Her home medications include 
torsemide, spironolactone, and lisinopril.  The patient’s most recent labs are significant for 
international normalized ratio (INR): 1.6 (0.9-1.1), total bilirubin: 2.4 mg/dL (0.3-1.0 mg/dL), 
serum albumin: 3.1 g/dL (3.5-5 g/dL), serum creatinine: 1.45 mg/dL (0.7-1.5 mg/dL), AST: 38 
units/L (8-42 units/L), ALT: 29 units/L (0-35 units/L).  It was determined that she is not a liver 
transplant candidate.   She decided to place a few limitations on her care after the transplant 
evaluation including do not resuscitate, do not intubate, and no artificial nutrition orders.  Her 
advance directive choices indicate that she is trending towards a more palliative approach to her 
medical care.  
This patient has compensated cirrhosis as evidenced by her lack of recent hospitalizations. She is 
a candidate for chronic acetaminophen 1 g by mouth three times a day to treat her OA knee pain 
Acetaminophen is a preferred analgesia for knee OA (57).  The suggested dose regimen is 
consistent with recent expert opinion recommendations.  However it is unclear if the patient 
would experience a clinically significant difference in analgesia or be at a higher risk for 
decompensation if a 2 g/day or 4 g/day regimen was chosen.  The patient would be at increased 
risk of hepatorenal syndrome and acute kidney injury with continued NSAID use given her 
Child-Pugh class B cirrhosis, stage 3 CKD, and diuretic use.   The patient is at increased risk of 
hepatotoxicity due to increased CYP2E1 activity in NASH patients (47). She should be 
counseled to stop acetaminophen and immediately contact her physician if she develops any 
signs and symptoms suggestive of decompensated cirrhosis as defined by EASL (e.g. ascites, 
bleeding, encephalopathy, or jaundice) (2).  It would be reasonable to obtain an INR, total 
bilirubin, albumin, electrolytes, and serum creatinine if this patient is develops decompensated 
cirrhosis and/or is hospitalized. 
Case 2:   
A 45 year old male with cirrhosis secondary to alcohol use disorder is admitted to the hospital 
for shortness of breath secondary to tense ascites. Other than the complaints listed above, the 
only other significant history is chronic back pain which has kept the patient out of work for the 
last several years.  The patient had been admitted approximately twice a month for the past year 
for episodes of tense ascites. The patient's home medications are lactulose, rifaximin, 
spironolactone, furosemide, nadalol, ciprofloxacin, and acetaminophen 1000 mg PO TID; all 
have been restarted in the hospital. The patient's compliance to his home medication regimen is 
uncertain and the patient endorses continuing to drink a pint or more of vodka daily.  The patient 
has a Child-Pugh score of 13 (Class C) and while not considered a transplant candidate, has a 
MELD score of 38.  
Due to the severity of liver disease, uncertainty of the adequacy of all metabolic pathways, and 
the possibility of reduced glutathione stores and CYP2E1 induction secondary to continued 
alcohol use acetaminophen should be discontinued. NSAIDs would not be an appropriate 
analgesic option for this patient due to concerns with hepatorenal syndrome and potential 
additional fluid retention. The patient should be referred to physical therapy or  could be 
considered for an opioid if an appropriate patient safety agreement could be developed.   
 
